Soleno Therapeutics Achieves First Profitable Year with $190.4M VYKAT XR Sales and $100M Share Repurchase

summarizeSummary

Soleno Therapeutics reported its first profitable year in 2025 with $190.4 million in VYKAT XR sales, a significant turnaround from previous losses, alongside a $100 million share repurchase and remediation of internal control weaknesses.

check_boxKey Events

• Achieves First Profitable Year

  The company reported a net income of $20.9 million for the year ended December 31, 2025, a significant turnaround from a net loss of $175.85 million in 2024.

• Strong VYKAT XR Revenue Growth

  Product revenue, net, reached $190.4 million in 2025, compared to zero in 2024, following the FDA approval and commercial launch of VYKAT XR in March 2025.

• Positive Operating Cash Flow

  Operating activities provided $46.8 million in net cash during 2025, a substantial improvement from using $69.1 million in 2024.

• Completes $100 Million Share Repurchase

  The company completed an accelerated share repurchase program for $100.0 million, repurchasing an aggregate of 2,174,050 shares at an average price of $46.00 per share.

auto_awesomeAnalysis

This annual report confirms a significant financial turnaround for Soleno Therapeutics, marking its first profitable year with substantial revenue generated from VYKAT XR sales. The company transitioned from a $175.85 million net loss in 2024 to a $20.9 million net income in 2025, driven by the successful commercialization of its lead product. Strong operating cash flow and a robust cash position further underscore its improved financial health. Additionally, the company executed a substantial $100 million accelerated share repurchase program and successfully remediated a previously identified material weakness in internal controls, enhancing investor confidence and operational integrity.